全文获取类型
收费全文 | 224篇 |
免费 | 0篇 |
专业分类
系统科学 | 5篇 |
理论与方法论 | 1篇 |
现状及发展 | 57篇 |
研究方法 | 49篇 |
综合类 | 105篇 |
自然研究 | 7篇 |
出版年
2021年 | 2篇 |
2020年 | 3篇 |
2019年 | 1篇 |
2018年 | 11篇 |
2017年 | 3篇 |
2016年 | 9篇 |
2015年 | 4篇 |
2014年 | 6篇 |
2013年 | 4篇 |
2012年 | 20篇 |
2011年 | 26篇 |
2010年 | 7篇 |
2009年 | 4篇 |
2008年 | 17篇 |
2007年 | 24篇 |
2006年 | 17篇 |
2005年 | 12篇 |
2004年 | 17篇 |
2003年 | 15篇 |
2002年 | 14篇 |
2000年 | 2篇 |
1979年 | 3篇 |
1969年 | 1篇 |
1967年 | 2篇 |
排序方式: 共有224条查询结果,搜索用时 0 毫秒
221.
de Lau W Barker N Low TY Koo BK Li VS Teunissen H Kujala P Haegebarth A Peters PJ van de Wetering M Stange DE van Es JE Guardavaccaro D Schasfoort RB Mohri Y Nishimori K Mohammed S Heck AJ Clevers H 《Nature》2011,476(7360):293-297
The adult stem cell marker Lgr5 and its relative Lgr4 are often co-expressed in Wnt-driven proliferative compartments. We find that conditional deletion of both genes in the mouse gut impairs Wnt target gene expression and results in the rapid demise of intestinal crypts, thus phenocopying Wnt pathway inhibition. Mass spectrometry demonstrates that Lgr4 and Lgr5 associate with the Frizzled/Lrp Wnt receptor complex. Each of the four R-spondins, secreted Wnt pathway agonists, can bind to Lgr4, -5 and -6. In HEK293 cells, RSPO1 enhances canonical WNT signals initiated by WNT3A. Removal of LGR4 does not affect WNT3A signalling, but abrogates the RSPO1-mediated signal enhancement, a phenomenon rescued by re-expression of LGR4, -5 or -6. Genetic deletion of Lgr4/5 in mouse intestinal crypt cultures phenocopies withdrawal of Rspo1 and can be rescued by Wnt pathway activation. Lgr5 homologues are facultative Wnt receptor components that mediate Wnt signal enhancement by soluble R-spondin proteins. These results will guide future studies towards the application of R-spondins for regenerative purposes of tissues expressing Lgr5 homologues. 相似文献
222.
Windbichler N Menichelli M Papathanos PA Thyme SB Li H Ulge UY Hovde BT Baker D Monnat RJ Burt A Crisanti A 《Nature》2011,473(7346):212-215
Genetic methods of manipulating or eradicating disease vector populations have long been discussed as an attractive alternative to existing control measures because of their potential advantages in terms of effectiveness and species specificity. The development of genetically engineered malaria-resistant mosquitoes has shown, as a proof of principle, the possibility of targeting the mosquito's ability to serve as a disease vector. The translation of these achievements into control measures requires an effective technology to spread a genetic modification from laboratory mosquitoes to field populations. We have suggested previously that homing endonuclease genes (HEGs), a class of simple selfish genetic elements, could be exploited for this purpose. Here we demonstrate that a synthetic genetic element, consisting of mosquito regulatory regions and the homing endonuclease gene I-SceI, can substantially increase its transmission to the progeny in transgenic mosquitoes of the human malaria vector Anopheles gambiae. We show that the I-SceI element is able to invade receptive mosquito cage populations rapidly, validating mathematical models for the transmission dynamics of HEGs. Molecular analyses confirm that expression of I-SceI in the male germline induces high rates of site-specific chromosomal cleavage and gene conversion, which results in the gain of the I-SceI gene, and underlies the observed genetic drive. These findings demonstrate a new mechanism by which genetic control measures can be implemented. Our results also show in principle how sequence-specific genetic drive elements like HEGs could be used to take the step from the genetic engineering of individuals to the genetic engineering of populations. 相似文献
223.
224.
DT Jones N Jäger M Kool T Zichner B Hutter M Sultan YJ Cho TJ Pugh V Hovestadt AM Stütz T Rausch HJ Warnatz M Ryzhova S Bender D Sturm S Pleier H Cin E Pfaff L Sieber A Wittmann M Remke H Witt S Hutter T Tzaridis J Weischenfeldt B Raeder M Avci V Amstislavskiy M Zapatka UD Weber Q Wang B Lasitschka CC Bartholomae M Schmidt C von Kalle V Ast C Lawerenz J Eils R Kabbe V Benes P van Sluis J Koster R Volckmann D Shih MJ Betts RB Russell S Coco GP Tonini U Schüller V Hans N Graf YJ Kim C Monoranu 《Nature》2012,488(7409):100-105
Medulloblastoma is an aggressively growing tumour, arising in the cerebellum or medulla/brain stem. It is the most common malignant brain tumour in children, and shows tremendous biological and clinical heterogeneity. Despite recent treatment advances, approximately 40% of children experience tumour recurrence, and 30% will die from their disease. Those who survive often have a significantly reduced quality of life. Four tumour subgroups with distinct clinical, biological and genetic profiles are currently identified. WNT tumours, showing activated wingless pathway signalling, carry a favourable prognosis under current treatment regimens. SHH tumours show hedgehog pathway activation, and have an intermediate prognosis. Group 3 and 4 tumours are molecularly less well characterized, and also present the greatest clinical challenges. The full repertoire of genetic events driving this distinction, however, remains unclear. Here we describe an integrative deep-sequencing analysis of 125 tumour-normal pairs, conducted as part of the International Cancer Genome Consortium (ICGC) PedBrain Tumor Project. Tetraploidy was identified as a frequent early event in Group 3 and 4 tumours, and a positive correlation between patient age and mutation rate was observed. Several recurrent mutations were identified, both in known medulloblastoma-related genes (CTNNB1, PTCH1, MLL2, SMARCA4) and in genes not previously linked to this tumour (DDX3X, CTDNEP1, KDM6A, TBR1), often in subgroup-specific patterns. RNA sequencing confirmed these alterations, and revealed the expression of what are, to our knowledge, the first medulloblastoma fusion genes identified. Chromatin modifiers were frequently altered across all subgroups. These findings enhance our understanding of the genomic complexity and heterogeneity underlying medulloblastoma, and provide several potential targets for new therapeutics, especially for Group 3 and 4 patients. 相似文献